Literature DB >> 28742222

Disruption of the ATP/adenosine balance in CD39-/- mice is associated with handling-induced seizures.

Amanda J Lanser1, Rafael M Rezende1, Stephen Rubino1, Paul J Lorello2, Dustin J Donnelly1, Huixin Xu1, Lauren A Lau3, Chris G Dulla3, Barbara J Caldarone4, Simon C Robson5, Howard L Weiner1.   

Abstract

Seizures are due to excessive, synchronous neuronal firing in the brain and are characteristic of epilepsy, the fourth most prevalent neurological disease. We report handling-induced and spontaneous seizures in mice deficient for CD39, a cell-surface ATPase highly expressed on microglial cells. CD39-/- mice with handling-induced seizures had normal input-output curves and paired-pulse ratio measured from hippocampal slices and lacked microgliosis, astrogliosis or overt cell loss in the hippocampus and cortex. As expected, however, the cerebrospinal fluid of CD39-/- mice contained increased levels of ATP and decreased levels of adenosine. To determine if immune activation was involved in seizure progression, we challenged mice with lipopolysaccharide (LPS) and measured the effect on microglia activation and seizure severity. Systemic LPS challenge resulted in increased cortical staining of Iba1/CD68 and gene array data from purified microglia predicted increased expression of interleukin-8, triggering receptor expressed on myeloid cells 1, p38, pattern recognition receptors, death receptor, nuclear factor-κB , complement, acute phase, and interleukin-6 signalling pathways in CD39-/- versus CD39+/+ mice. However, LPS treatment did not affect handling-induced seizures. In addition, microglia-specific CD39 deletion in adult mice was not sufficient to cause seizures, suggesting instead that altered expression of CD39 during development or on non-microglial cells such as vascular endothelial cells may promote the seizure phenotype. In summary, we show a correlation between altered extracellular ATP/adenosine ratio and a previously unreported seizure phenotype in CD39-/- mice. This work provides groundwork for further elucidation of the underlying mechanisms of epilepsy.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990ATPzzm321990; CD39; adenosine; epilepsy; microglia; seizure

Mesh:

Substances:

Year:  2017        PMID: 28742222      PMCID: PMC5680053          DOI: 10.1111/imm.12798

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  77 in total

Review 1.  The role of inflammation in epilepsy.

Authors:  Annamaria Vezzani; Jacqueline French; Tamas Bartfai; Tallie Z Baram
Journal:  Nat Rev Neurol       Date:  2010-12-07       Impact factor: 42.937

2.  Effectiveness of first antiepileptic drug.

Authors:  P Kwan; M J Brodie
Journal:  Epilepsia       Date:  2001-10       Impact factor: 5.864

3.  Assignment of ecto-nucleoside triphosphate diphosphohydrolase-1/cd39 expression to microglia and vasculature of the brain.

Authors:  N Braun; J Sévigny; S C Robson; K Enjyoji; O Guckelberger; K Hammer; F Di Virgilio; H Zimmermann
Journal:  Eur J Neurosci       Date:  2000-12       Impact factor: 3.386

4.  The ectonucleotidase cd39/ENTPDase1 modulates purinergic-mediated microglial migration.

Authors:  Katrin Färber; Sören Markworth; Ulrike Pannasch; Christiane Nolte; Vincent Prinz; Golo Kronenberg; Karen Gertz; Matthias Endres; Ingo Bechmann; Keiichi Enjyoji; Simon C Robson; Helmut Kettenmann
Journal:  Glia       Date:  2008-02       Impact factor: 7.452

5.  Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease.

Authors:  Jorge J Palop; Jeannie Chin; Erik D Roberson; Jun Wang; Myo T Thwin; Nga Bien-Ly; Jong Yoo; Kaitlyn O Ho; Gui-Qiu Yu; Anatol Kreitzer; Steven Finkbeiner; Jeffrey L Noebels; Lennart Mucke
Journal:  Neuron       Date:  2007-09-06       Impact factor: 17.173

6.  Investigation of the cingulate cortex in idiopathic generalized epilepsy.

Authors:  Aline M da S Braga; Elaine K Fujisao; Roberto C Verdade; Rômulo P Paschoalato; Ricardo P Paschoalato; Seizo Yamashita; Luiz E Betting
Journal:  Epilepsia       Date:  2015-09-28       Impact factor: 5.864

7.  Modulating inflammatory monocytes with a unique microRNA gene signature ameliorates murine ALS.

Authors:  Oleg Butovsky; Shafiuddin Siddiqui; Galina Gabriely; Amanda J Lanser; Ben Dake; Gopal Murugaiyan; Camille E Doykan; Pauline M Wu; Reddy R Gali; Lakshmanan K Iyer; Robert Lawson; James Berry; Anna M Krichevsky; Merit E Cudkowicz; Howard L Weiner
Journal:  J Clin Invest       Date:  2012-08-06       Impact factor: 14.808

8.  Epilepsy and neuron loss in the hippocampus.

Authors:  A M Dam
Journal:  Epilepsia       Date:  1980-12       Impact factor: 5.864

9.  What Elements of the Inflammatory System Are Necessary for Epileptogenesis In Vitro?

Authors:  Kyung-Il Park; Volodymyr Dzhala; Yero Saponjian; Kevin J Staley
Journal:  eNeuro       Date:  2015-03-25

10.  ATP Induces Disruption of Tight Junction Proteins via IL-1 Beta-Dependent MMP-9 Activation of Human Blood-Brain Barrier In Vitro.

Authors:  Fuxing Yang; Kai Zhao; Xiufeng Zhang; Jun Zhang; Bainan Xu
Journal:  Neural Plast       Date:  2016-10-04       Impact factor: 3.599

View more
  10 in total

Review 1.  Targeting CD39 in cancer.

Authors:  Achim K Moesta; Xian-Yang Li; Mark J Smyth
Journal:  Nat Rev Immunol       Date:  2020-07-29       Impact factor: 53.106

2.  Effects of the ecto-ATPase apyrase on microglial ramification and surveillance reflect cell depolarization, not ATP depletion.

Authors:  Christian Madry; I Lorena Arancibia-Cárcamo; Vasiliki Kyrargyri; Victor T T Chan; Nicola B Hamilton; David Attwell
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-30       Impact factor: 11.205

3.  CD73 or CD39 Deletion Reveals Different Mechanisms of Formation for Spontaneous and Mechanically Stimulated Adenosine and Sex Specific Compensations in ATP Degradation.

Authors:  Ying Wang; Jeffrey Copeland; Mimi Shin; Yuanyu Chang; B Jill Venton
Journal:  ACS Chem Neurosci       Date:  2020-03-04       Impact factor: 4.418

Review 4.  Microglial signatures and their role in health and disease.

Authors:  Oleg Butovsky; Howard L Weiner
Journal:  Nat Rev Neurosci       Date:  2018-10       Impact factor: 34.870

Review 5.  The mitochondrial biogenesis signaling pathway is a potential therapeutic target for myasthenia gravis via energy metabolism (Review).

Authors:  Lingling Ke; Qing Li; Jingwei Song; Wei Jiao; Aidong Ji; Tongkai Chen; Huafeng Pan; Yafang Song
Journal:  Exp Ther Med       Date:  2021-05-02       Impact factor: 2.447

Review 6.  Glial Purinergic Signaling in Neurodegeneration.

Authors:  Marie J Pietrowski; Amr Ahmed Gabr; Stanislav Kozlov; David Blum; Annett Halle; Kevin Carvalho
Journal:  Front Neurol       Date:  2021-05-14       Impact factor: 4.003

Review 7.  Purinergic signaling in infectious diseases of the central nervous system.

Authors:  Vinícius Santos Alves; Raíssa Leite-Aguiar; Joyce Pereira da Silva; Robson Coutinho-Silva; Luiz Eduardo Baggio Savio
Journal:  Brain Behav Immun       Date:  2020-07-24       Impact factor: 7.217

Review 8.  P2X7 Receptors Amplify CNS Damage in Neurodegenerative Diseases.

Authors:  Peter Illes
Journal:  Int J Mol Sci       Date:  2020-08-20       Impact factor: 5.923

9.  IL-4 prevents adenosine-mediated immunoregulation by inhibiting CD39 expression.

Authors:  Fengqin Fang; Wenqiang Cao; Yunmei Mu; Hirohisa Okuyama; Lingjie Li; Jingtao Qiu; Cornelia M Weyand; Jörg J Goronzy
Journal:  JCI Insight       Date:  2022-06-22

10.  Negative feedback control of neuronal activity by microglia.

Authors:  Ana Badimon; Hayley J Strasburger; Pinar Ayata; Xinhong Chen; Aditya Nair; Ako Ikegami; Philip Hwang; Andrew T Chan; Steven M Graves; Joseph O Uweru; Carola Ledderose; Munir Gunes Kutlu; Michael A Wheeler; Anat Kahan; Masago Ishikawa; Ying-Chih Wang; Yong-Hwee E Loh; Jean X Jiang; D James Surmeier; Simon C Robson; Wolfgang G Junger; Robert Sebra; Erin S Calipari; Paul J Kenny; Ukpong B Eyo; Marco Colonna; Francisco J Quintana; Hiroaki Wake; Viviana Gradinaru; Anne Schaefer
Journal:  Nature       Date:  2020-09-30       Impact factor: 69.504

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.